A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To estimate the 6 month progression free locally advanced or metastatic hepatocellular carcinoma (HCC) with no prior chemotherapy for HCC treated with BMS-582664.
throughout the study
No
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
United States: Food and Drug Administration
CA182-006
NCT00355238
December 2006
April 2010
Name | Location |
---|---|
MD Anderson Cancer Center | Houston, Texas 77030-4096 |
University of Iowa Hospitals and Clinics | Iowa City, Iowa 52242 |
Medical College of Wisconsin | Milwaukee, Wisconsin 53226 |
Albert Einstein Cancer Center | Philadelphia, Pennsylvania 19141 |
City of Hope National Medical Center | Los Angeles, California 91010 |
Duke University Medical Center | Durham, North Carolina 27710 |
Wayne State University | Detroit, Michigan 48202 |
University of Chicago | Chicago, Illinois 60637 |
Northwestern University Feinberg School of Medicine | Chicago, Illinois 60611 |
The Cancer Center at Hackensack University Medical Center | Hackensack, New Jersey 07601 |
Penn State Milton S. Hershey Medical Center | Hershey, Pennsylvania 17033 |
Christiana Care Health Services | Newark, Delaware 19713 |
University Of Miami Miller School Of Medicine | Miami, Florida 33010 |
Harbor-UCLA Medical Center | Torrance, California 90509 |
Univ Of Texas Southwestern | Dallas, Texas 75390 |